EGFR and non-small cell lung carcinoma: However, the above-mentioned studies are limited by small patient numbers and the use of early generation EGFR-TKIs, thus they do not support the superior efficacy or comparable safety of tested TKI regimens in locally advanced (LA)-NSCLC.